SG11201600385TA - Polymorph of syk inhibitors - Google Patents
Polymorph of syk inhibitorsInfo
- Publication number
- SG11201600385TA SG11201600385TA SG11201600385TA SG11201600385TA SG11201600385TA SG 11201600385T A SG11201600385T A SG 11201600385TA SG 11201600385T A SG11201600385T A SG 11201600385TA SG 11201600385T A SG11201600385T A SG 11201600385TA SG 11201600385T A SG11201600385T A SG 11201600385TA
- Authority
- SG
- Singapore
- Prior art keywords
- polymorph
- syk inhibitors
- syk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860197P | 2013-07-30 | 2013-07-30 | |
| PCT/US2014/048733 WO2015017460A1 (en) | 2013-07-30 | 2014-07-29 | Polymorph of syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600385TA true SG11201600385TA (en) | 2016-02-26 |
Family
ID=51301367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600385TA SG11201600385TA (en) | 2013-07-30 | 2014-07-29 | Polymorph of syk inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20160168155A1 (en) |
| EP (1) | EP3027618B1 (en) |
| JP (1) | JP6230709B2 (en) |
| KR (1) | KR101810798B1 (en) |
| CN (1) | CN105452252A (en) |
| AP (1) | AP2016009008A0 (en) |
| AR (1) | AR097158A1 (en) |
| AU (2) | AU2014296308C1 (en) |
| CA (1) | CA2919661C (en) |
| CL (1) | CL2016000238A1 (en) |
| CR (1) | CR20160098A (en) |
| DK (1) | DK3027618T3 (en) |
| EA (2) | EA201791873A1 (en) |
| ES (1) | ES2822285T3 (en) |
| HK (1) | HK1222390A1 (en) |
| HR (1) | HRP20201582T1 (en) |
| HU (1) | HUE052090T2 (en) |
| IL (1) | IL243579A0 (en) |
| MD (1) | MD4659B1 (en) |
| MX (1) | MX2016001304A (en) |
| MY (1) | MY176803A (en) |
| NZ (1) | NZ715776A (en) |
| PE (1) | PE20160862A1 (en) |
| PH (1) | PH12016500169A1 (en) |
| PL (1) | PL3027618T3 (en) |
| PT (1) | PT3027618T (en) |
| SG (1) | SG11201600385TA (en) |
| SI (1) | SI3027618T1 (en) |
| SV (1) | SV2016005149A (en) |
| TW (1) | TW201602108A (en) |
| UY (1) | UY35683A (en) |
| WO (1) | WO2015017460A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201707798SA (en) | 2008-12-08 | 2017-10-30 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
| WO2011112995A1 (en) | 2010-03-11 | 2011-09-15 | Gilead Sciences, Inc. | Imidazopyridines syk inhibitors |
| TW201602108A (en) | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | Polymorph of Syk inhibitors |
| MD4684B1 (en) | 2013-07-30 | 2020-03-31 | Gilead Connecticut INc. | Imidazopyrazine-based formulations as SYK inhibitors |
| ES2835549T3 (en) | 2013-12-04 | 2021-06-22 | Kronos Bio Inc | Cancer treatment methods |
| UY35898A (en) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| CA2955180A1 (en) | 2014-07-14 | 2016-01-21 | Gilead Sciences, Inc. | Combinations comprising entospletinib and a vinca-alkaloid for treating cancers |
| TW201639573A (en) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | Combination therapies for treating cancers |
| JP2018513173A (en) | 2015-04-21 | 2018-05-24 | ギリアード サイエンシーズ， インコーポレイテッド | Treatment of chronic graft-versus-host disease with SYK inhibitors |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| WO2017144010A1 (en) * | 2016-02-26 | 2017-08-31 | 苏州晶云药物科技有限公司 | New crystalline forms of (6-(1h-indazol-6-yl)-n-[4-(4-morpholinyl)phenyl]imidazo[1,2-a]pyrazin-8-amine) methanesulfonate |
| TW201822764A (en) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk inhibitors |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| KR102399996B1 (en) * | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Polymorphs of SYK Inhibitors |
| EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| JP7242702B2 (en) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | PD-1/PD-L1 inhibitor |
| JP6899975B2 (en) | 2018-05-14 | 2021-07-07 | ギリアード サイエンシーズ， インコーポレイテッド | MCL-1 inhibitor |
| PT3820572T (en) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020172431A1 (en) | 2019-02-22 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
| CN113402506B (en) * | 2021-06-17 | 2023-06-16 | 四川大学 | Intermediate, preparation method and application thereof in synthesizing vinca-bunting |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607813B1 (en) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | ALKYLAMINO-8 IMIDAZO (1,2-A) PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (en) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337609A1 (en) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Novel pyrazinecarboxamide derivatives, their preparation and their use in medicines |
| DE4337611A1 (en) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | New benzoylguanidines, their preparation and their use in medicines |
| FR2711993B1 (en) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Drugs containing 7H-imidazol [1,2-a] pyrazine-8-one derivatives, new compounds and their preparation. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE372966T1 (en) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | IMPROVED EFFECTIVENESS OF DRUGS THROUGH DEUTERATION |
| FR2723373B1 (en) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | PURIFIED FORM OF STREPTOGRAMINS, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| WO1996034866A1 (en) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| SE9704404D0 (en) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DE19948434A1 (en) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amines |
| JP2001302667A (en) | 2000-04-28 | 2001-10-31 | Bayer Ag | Imidazopyrimidine derivative and triazolopyrimidine derivative |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (en) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| WO2003089434A2 (en) | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| DE60326341D1 (en) | 2002-05-14 | 2009-04-09 | Xenova Ltd | PROCESS FOR PREPARING ANTHRANILIC ACID DERIVATIVE HYDRATE |
| WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| NZ538566A (en) | 2002-09-19 | 2008-02-29 | Schering Corp | Imidazopyridines as cyclin dependent kinase inhibitors |
| KR20060010709A (en) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| ES2293015T3 (en) | 2002-09-23 | 2008-03-16 | Schering Corporation | IMIDAZOPIRAZINAS AS INHIBITORS OF CYCLINE DEPENDENT KINDERS. |
| US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
| EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
| JP5031760B2 (en) | 2005-11-10 | 2012-09-26 | シェーリング コーポレイション | Imidazopyrazine as a protein kinase inhibitor |
| EP2057158B8 (en) | 2006-08-30 | 2015-09-30 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| AR063706A1 (en) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
| CL2008002793A1 (en) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others |
| JP5563472B2 (en) | 2007-11-28 | 2014-07-30 | アイ アール エックス セーラピューティクス， インコーポレイテッド | Methods for increasing immunological effects |
| WO2009077334A1 (en) | 2007-12-14 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
| AU2009215191A1 (en) | 2008-02-13 | 2009-08-20 | Gilead Connecticut, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| US20110002989A1 (en) | 2008-03-07 | 2011-01-06 | Pfizer Inc. | Methods, dosage forms and kits for administering ziprasidone without food |
| CA2728016C (en) | 2008-06-24 | 2017-02-28 | F. Hoffmann-La Roche Ag | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| JP5490789B2 (en) | 2008-07-02 | 2014-05-14 | エフ．ホフマン−ラ ロシュ アーゲー | Novel phenylpyrazinones as kinase inhibitors |
| ES2552681T3 (en) | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | New phenyl-imidazopyridines and pyridazines |
| TWI453207B (en) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| PE20120058A1 (en) * | 2008-12-08 | 2012-02-02 | Gilead Connecticut Inc | IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS |
| SG10201707798SA (en) | 2008-12-08 | 2017-10-30 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
| US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2453477T3 (en) | 2009-12-18 | 2014-04-07 | Frieslandcampina Nederland Holding B.V. | Composition of coprocessed excipient for a tablet, its preparation and use |
| WO2011112995A1 (en) | 2010-03-11 | 2011-09-15 | Gilead Sciences, Inc. | Imidazopyridines syk inhibitors |
| CN107266435A (en) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | The salt and crystalline form of cell death inducer |
| JPWO2012147832A1 (en) * | 2011-04-27 | 2014-07-28 | 第一三共株式会社 | Crystals of phenylpyrrole derivatives |
| WO2013188856A1 (en) | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US20140051696A1 (en) | 2012-08-14 | 2014-02-20 | Gilead Calistoga Llc | Therapies for treating cancer |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
| TW201602108A (en) | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | Polymorph of Syk inhibitors |
| MD4684B1 (en) | 2013-07-30 | 2020-03-31 | Gilead Connecticut INc. | Imidazopyrazine-based formulations as SYK inhibitors |
| WO2015017610A1 (en) | 2013-07-31 | 2015-02-05 | Gilead Sciences, Inc. | Syk inhibitors |
| ES2835549T3 (en) | 2013-12-04 | 2021-06-22 | Kronos Bio Inc | Cancer treatment methods |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| UY35898A (en) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. |
| CN116813596A (en) | 2013-12-23 | 2023-09-29 | 吉利德科学公司 | Macrocyclic HCV NS3 inhibits tripeptide synthesis |
| TW201617074A (en) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Syk inhibitors |
| CA2955180A1 (en) | 2014-07-14 | 2016-01-21 | Gilead Sciences, Inc. | Combinations comprising entospletinib and a vinca-alkaloid for treating cancers |
| TW201639573A (en) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | Combination therapies for treating cancers |
| JP2018513173A (en) | 2015-04-21 | 2018-05-24 | ギリアード サイエンシーズ， インコーポレイテッド | Treatment of chronic graft-versus-host disease with SYK inhibitors |
-
2014
- 2014-07-29 TW TW103125870A patent/TW201602108A/en unknown
- 2014-07-29 ES ES14750289T patent/ES2822285T3/en active Active
- 2014-07-29 EP EP14750289.2A patent/EP3027618B1/en active Active
- 2014-07-29 JP JP2016531837A patent/JP6230709B2/en active Active
- 2014-07-29 SG SG11201600385TA patent/SG11201600385TA/en unknown
- 2014-07-29 DK DK14750289.2T patent/DK3027618T3/en active
- 2014-07-29 US US14/907,767 patent/US20160168155A1/en not_active Abandoned
- 2014-07-29 KR KR1020167005206A patent/KR101810798B1/en active IP Right Grant
- 2014-07-29 MY MYPI2016700285A patent/MY176803A/en unknown
- 2014-07-29 CN CN201480043503.5A patent/CN105452252A/en active Pending
- 2014-07-29 PT PT147502892T patent/PT3027618T/en unknown
- 2014-07-29 PL PL14750289T patent/PL3027618T3/en unknown
- 2014-07-29 AP AP2016009008A patent/AP2016009008A0/en unknown
- 2014-07-29 MD MD20160017A patent/MD4659B1/en not_active IP Right Cessation
- 2014-07-29 PE PE2016000197A patent/PE20160862A1/en unknown
- 2014-07-29 US US14/446,011 patent/US9657023B2/en active Active
- 2014-07-29 SI SI201431675T patent/SI3027618T1/en unknown
- 2014-07-29 EA EA201791873A patent/EA201791873A1/en unknown
- 2014-07-29 AU AU2014296308A patent/AU2014296308C1/en not_active Ceased
- 2014-07-29 MX MX2016001304A patent/MX2016001304A/en unknown
- 2014-07-29 EA EA201690172A patent/EA029281B1/en active IP Right Revival
- 2014-07-29 WO PCT/US2014/048733 patent/WO2015017460A1/en active Application Filing
- 2014-07-29 HU HUE14750289A patent/HUE052090T2/en unknown
- 2014-07-29 NZ NZ715776A patent/NZ715776A/en unknown
- 2014-07-29 CA CA2919661A patent/CA2919661C/en active Active
- 2014-07-30 AR ARP140102857A patent/AR097158A1/en unknown
- 2014-07-30 UY UY35683A patent/UY35683A/en not_active Application Discontinuation
-
2016
- 2016-01-12 IL IL243579A patent/IL243579A0/en unknown
- 2016-01-25 PH PH12016500169A patent/PH12016500169A1/en unknown
- 2016-01-29 SV SV2016005149A patent/SV2016005149A/en unknown
- 2016-01-29 CL CL2016000238A patent/CL2016000238A1/en unknown
- 2016-02-29 CR CR20160098A patent/CR20160098A/en unknown
- 2016-09-05 HK HK16110532.6A patent/HK1222390A1/en unknown
-
2017
- 2017-04-11 US US15/484,844 patent/US20170217967A1/en not_active Abandoned
- 2017-09-08 AU AU2017225136A patent/AU2017225136A1/en not_active Abandoned
- 2017-10-19 US US15/788,583 patent/US10266539B2/en active Active
-
2020
- 2020-10-05 HR HRP20201582TT patent/HRP20201582T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222390A1 (en) | Polymorph of syk inhibitors syk | |
| HK1256999A1 (en) | Syk inhibitors | |
| HK1222329A1 (en) | Formulation of syk inhibitors syk | |
| IL243578A0 (en) | Syk inhibitors | |
| GB201410735D0 (en) | Method of inhibiting DYRK1B | |
| HK1211024A1 (en) | Inhibitors of syk syk | |
| HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
| IL240763A0 (en) | Halogenopyrazoles as inhibitors of therombin | |
| EP3003320A4 (en) | Novel polymorph of regadenoson | |
| ZA201507100B (en) | Synthesis of bace1 inhibitors | |
| HK1221159A1 (en) | Inhibitors of metastasis | |
| EP2959896A4 (en) | Inhibitor of tprotein phosphorylation |